Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 May 17;18(1):108.
doi: 10.1186/s13075-016-1009-y.

Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker

Yong Gil Hwang  1 , Goundappa K Balasubramani  2 , Ilinca D Metes  3 , Marc C Levesque  3   4 , S Louis Bridges Jr  5 , Larry W Moreland  3
Affiliations
Randomized Controlled Trial

Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker

Yong Gil Hwang et al. Arthritis Res Ther. .

Abstract

Background: The aim was to compare the effect of etanercept (ETN) and conventional synthetic disease-modifying anti-rheumatic drug (DMARD) therapy on serum amyloid A (SAA) levels and to determine whether SAA reflects rheumatoid arthritis (RA) disease activity better than C-reactive protein (CRP).

Methods: We measured SAA and CRP at baseline, 24, 48, and 102 week follow-up visits in 594 patients participating in the Treatment of early RA (TEAR) study. We used Spearman correlation coefficients (rho) to evaluate the relationship between SAA and CRP and mixed effects models to determine whether ETN and methotrexate (MTX) treatment compared to triple DMARD therapy differentially lowered SAA. Akaike information criteria (AIC) were used to determine model fits.

Results: SAA levels were only moderately correlated with CRP levels (rho = 0.58, p < 0.0001). There were significant differences in SAA by both visit (p = 0.0197) and treatment arm (p = 0.0130). RA patients treated with ETN plus MTX had a larger reduction in SAA than patients treated with traditional DMARD therapy. Similar results were found for serum CRP by visit (p = 0.0254) and by treatment (p < 0.0001), with a more pronounced difference than for SAA. Across all patients and time points, models of the disease activity score of 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) using SAA levels were better than models using CRP; the ΔAIC between the SAA and CRP models was 305.

Conclusions: SAA may be a better biomarker of RA disease activity than CRP, especially during treatment with tumor necrosis factor (TNF) antagonists. This warrants additional studies in other cohorts of patients on treatment for RA.

Trial registration: (ClinicalTrials.gov identifier: NCT00259610 , Date of registration: 28 November 2005).

Keywords: C-reactive protein; Early rheumatoid arthritis; Etanercept; Serum amyloid A.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Serum amyloid A (SAA) (mg/L) and C-reactive protein (CRP) (mg/L) at the baseline study visit
Fig. 2
Fig. 2
Mean serum amyloid A (SAA) (a) and C-reactive protein (CRP) (b) by treatment modality and study visit. MTX methotrexate, ETN etanercept, DMARD disease-modifying anti-rheumatic drug. Error bar denotes standard deviation
See this image and copyright information in PMC

References

    1. Thompson PW, Silman AJ, Kirwan JR, Currey HL. Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum. 1987;30(6):618–23. doi: 10.1002/art.1780300603. - DOI - PubMed
    1. Devlin J, Gough A, Huissoon A, Perkins P, Holder R, Reece R, et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol. 1997;24(1):9–13. - PubMed
    1. van Leeuwen MA, van Rijswijk MH, van der Heijde DM, Te Meerman GJ, van Riel PL, Houtman PM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol. 1993;32(Suppl 3):9–13. doi: 10.1093/rheumatology/32.suppl_3.9. - DOI - PubMed
    1. van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol. 1994;21(3):425–9. - PubMed
    1. Prevoo ML, MA v ‘t, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8. doi: 10.1002/art.1780380107. - DOI - PubMed

Publication types

Associated data